<DOC>
	<DOCNO>NCT00806156</DOCNO>
	<brief_summary>This multicenter , open-label , two-arm , 2-stage , Phase 2 study NKTR-102 patient metastatic locally advanced platinum-resistant ovarian cancer . Approximately 70 patient randomize 1:1 one two treatment arm . NKTR-102 administer dose level 145 mg/m2 arm . In Arm A , NKTR-102 give q14d schedule . In Arm B , NKTR-102 give q21d schedule . After initial 70 patient enrol , Arm B enroll approximately 110 additional patient .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy NKTR-102 Patients With Metastatic Locally Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis epithelial ovarian cancer , primary peritoneal cancer fallopian tube cancer 2 . Inoperable metastatic locally advanced ovarian cancer 3 . Platinumresistant ovarian cancer define progression RECIST within 6 month last dose recent platinum drug 4 . Platinumresistant patient progress receive PLD ( Doxil/Caelyx ) therapy platinumresistant set otherwise unable receive PLD therapy . 5 . Diseases must measurable defined RECIST least 1 lesion previously irradiate . 6 . ECOG performance score 0 1 . 7 . Adequate organ bone marrow function Screening . 1 . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) recover NCICTCAE grade 1 toxicity prior Day 1 Cycle 1 2 . Patients major surgery within 4 week prior Day 1 Cycle 1 minor surgery within 2 week prior Day 1 Cycle 1 3 . Patients receive CYP3A4 inducer inhibitor . 4 . Patients receive treatment camptothecin derivative ( eg . irinotecan , topotecan , SN38 investigational agent , etc. ) . 5 . Patients CNS metastasis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>